Invest in a Research Portfolio
Thanks to concerned donors, The Leukemia & Lymphoma Society (LLS) has worldwide research commitments that exceed a quarter of a billion dollars. But our research investment isn't fully realized until every blood cancer patient is cured or able to manage his or her disease with good quality of life.
When you make a gift of $10,000 or more, consider supporting an LLS research portfolio. By investing in a disease-specific portfolio, you can support multiple research projects that focus on the specific blood cancer that concerns you. What's more, 100 percent of your donation is invested in research without any LLS overhead expenses.
LLS grants aren't confined to a single institution, so you can support the most promising research at leading cancer centers and universities. Current LLS research portfolios include the following categories:
- acute lymphoblastic leukemia
- acute myeloid leukemia
- blood cancer diagnostics
- chronic lymphocytic leukemia
- chronic myeloid leukemia
- Hodgkin lymphoma
- non-Hodgkin lymphoma (aggressive)
- non-Hodgkin lymphoma (indolent)
- pediatric blood cancers
- quality of life
- stem cell transplantation
- targeted therapy
- therapy acceleration funding opportunities
All LLS-funded research is vetted by renowned biomedical advisors. These distinguished experts help LLS select for funding the most promising projects and researchers at leading universities and cancer centers, in line with evolving scientific opportunities and medical needs.
To keep you abreast of the latest research advances, we'll send you annual portfolio progress reports and timely news of scientific and medical breakthroughs.
These portfolios are representative samples of LLS-funded research. If you don't see your topic of interest here, contact our Philanthropy staff.
The Research Story So Far
LLS-funded researchers have already helped improve outcomes for blood cancer patients with advances in diagnostics, stem cell transplantation, combination chemotherapies and safe and effective targeted therapies like Gleevec, Rituxan and Velcade.
Get More Information
Contact Richard Schneyer, Vice President of Development, at firstname.lastname@example.org or (914) 821-8978.